Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New markers may spot ovarian cancer earlier

NCT ID NCT02326064

Diagnosis Sponsor: Centre Hospitalier Departemental Vendee Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether adding a new tumor marker (HE4) and using special scoring systems (ROMA and RMI) can better tell the difference between harmless ovarian cysts and ovarian cancer. Researchers measured CA125 and HE4 levels in 221 women scheduled for ovarian cyst surgery. The goal was to improve early diagnosis and reduce uncertainty.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

221 people

The number who actually took part.

Start date

May 2015

Finished

Jun 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient hospitalized for surgery for presumed benign ovarian tumor

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients to undergo surgery for an ovarian cyst * presumed benign ovarian tumor (according to the rules of the IOTA(International Ovarian Tumor Analysis Group) group) * agreement to participate in the study Exclusion Criteria: * pregnant patient * minor patient * Patient under guardianship, trusteeship, or deprived of liberty * Patient with ascites or metastases or malignant ovarian mass presumed under the rules of IOTA group. * Patient with an adnexal torsion is suspected * Patient unable to understand the proposed study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Benign ovarian tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian benign neoplasm ovarian cancer ovarian neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer Ovarian tumor

Contacts and locations

Locations

  • CH de Saint Nazaire

    Saint-Nazaire, 44606, France

  • CHD Vendée

    La Roche-sur-Yon, 85925, France

  • CHU de Nantes

    Nantes, 44093, France

  • Centre Hospitalier de Cholet

    Cholet, 49300, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.